Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. The company is headquartered in Melbourne, Victoria. The company went IPO on 2004-12-16. The company has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates. The company is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease, and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for advanced chronic heart failure (REVASCOR) and chronic low back pain (MPC-06-ID). Two products have been commercialized in Japan and Europe by the Company's licensees. The company has established commercial partnerships in Europe and China for certain Phase III assets.
Follow-Up Questions
Who is the CEO of Mesoblast Ltd?
Dr. Silviu Itescu is the Chief Executive Officer of Mesoblast Ltd, joining the firm since 2004.
What is the price performance of MEOBF stock?
The current price of MEOBF is $1.45, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Mesoblast Ltd?
Mesoblast Ltd belongs to Biotechnology industry and the sector is Health Care
What is Mesoblast Ltd market cap?
Mesoblast Ltd's current market cap is $185.7M
Is Mesoblast Ltd a buy, sell, or hold?
According to wall street analysts, 5 analysts have made analyst ratings for Mesoblast Ltd, including 1 strong buy, 7 buy, 2 hold, 0 sell, and 1 strong sell
